Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in people with overweight or obesity and cardiovascular disease. Early waist reduction explained only a third of this benefit, showing that semaglutide’s heart protection extends beyond fat loss.